Castle Biosciences (CSTL) Amortization - Intangibles (2021 - 2026)

Castle Biosciences (CSTL) has 6 years of Amortization - Intangibles data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Amortization - Intangibles fell 92.23% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (down 75.17% YoY) and the FY2025 annual result came in at $34.8 million, up 213.51% from the prior year.
• Amortization - Intangibles eased to $2.2 million in Q1 2026 per CSTL's latest filing, from $2.2 million in the prior quarter.
• The five-year high for Amortization - Intangibles was $28.3 million in Q1 2025, with the low at $1.6 million in Q1 2022.
• Average Amortization - Intangibles over 5 years is $3.7 million, with a median of $2.2 million recorded in 2025.
• Year-over-year, Amortization - Intangibles jumped 1187.5% in 2025 and sank 92.23% in 2026.
• Castle Biosciences' Amortization - Intangibles stood at $2.2 million in 2022, then gained by 6.19% to $2.3 million in 2023, then retreated by 8.7% to $2.1 million in 2024, then rose by 6.57% to $2.2 million in 2025, then retreated by 1.7% to $2.2 million in 2026.
• Business Quant data shows CSTL's Amortization - Intangibles at $2.2 million in Q1 2026, $2.2 million in Q4 2025, and $2.3 million in Q3 2025.